55279-29-3

Basic information

• Product Name: 3-AMINO-PYRIDINE-4-CARBALDEHYDE
• Synonyms: 3-AMINO-PYRIDINE-4-CARBALDEHYDE;3-AMINOPYRIDINE-4-CARBOXALDEHYDE;3-AMINOISONICOTINALDEHYDE;3-AMINO-4-PYRIDINECARBOXALDEHYDE;3-AMINO-4-CARBOXALDEHYDE;3-Aminopyridine-4-carboxaldehyde 97%;3-AMINO-PYRIDINE-4-C;3-Aminoisonicotinaldehyde 97%
• CAS NO: 55279-29-3
• Molecular Formula: C₆H₆N₂O
• Molecular Weight: 122.12
• Product Categories: Pyridine series;Aldehydes;Pyridines;Amines;Aromatics;Heterocycles;Intermediates;Heterocycle-Pyridine series
• Mol File: 55279-29-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: ca 92℃
• Boiling Point: 333.3 °C at 760 mmHg
• Flash Point: 155.4 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 0.000138mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.19±0.18(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(55279-29-3)
• EPA Substance Registry System: 3-AMINO-PYRIDINE-4-CARBALDEHYDE(55279-29-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 55279-29-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 55279-29-3 differently. You can refer to the following data:
1. 3-Amino-pyridine-4-carbaldehyde is used in the preparation of hydroxyquinolin-2(1H)-ones and derivatives thereof for treating cognitive-related disorders and neuropathic pain disorders.
2. 3-Aminopyridine-4-carboxaldehyde is used as pharmaceutical intermediate.

InChI:InChI=1/C6H6N2O/c7-6-3-8-2-1-5(6)4-9/h1-4H,7H2

Upstream product

• 116026-95-0 3--4-pyridinecarboxaldehyde 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 1352037-93-4 N-methoxy-N-methyl 3-amino-isonicotinamide 
• 55279-30-6 methyl 3-aminoisonicotinate 
• 103698-10-8 methyl 3-nitropyridine-4-carboxylate 
• 14208-83-4 ethyl 3-aminopyridine-4-carboxylate 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 4664-01-1 3,4-pyridinedicarboximide 
• 152398-05-5 (3-amino-pyridin-4-yl)methanol 

Downstream Products

• 316155-87-0 2-carboxy-(1,6)-naphthyridine 
• 1352037-95-6 3-phenyl-2-(pyridin-4-yl)-1,7-naphthyridine 
• 55234-64-5 2-oxo-1,2-dihydro-[1,7]naphthyridine-3-carboxylic acid ethyl ester 
• 1427555-54-1 4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)morpholine 
• 1427555-52-9 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid hydrochloride 
• 1609355-78-3 C₁₄H₁₀ClN₃ 
• 1609355-77-2 2-(2-chloro-5-nitrophenyl)-1,7-naphthyridine 
• 1427588-42-8 3-cyclopropyl-1-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)urea 
• 1427588-41-7 propan-2-yl N-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)carbamate 
• 1427589-25-0 tert-butyl N-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)carbamate 
• 1427588-97-3 tert-butyl 4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)piperazine-1-carboxylate 
• 1334713-60-8 tert-butyl N-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)carbamate 
• 1427588-51-9 4-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)-N-ethylpiperazine-1-carboxamide 
• 1427556-00-0 N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide 

Relevant articles and documents

BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is -NR3aC(O)-, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are indepndently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.

Synthesis of novel 1,7-naphthyridines by Friedlaender condensation of pyridine substrates

The general ability of appropriate pyridyl compounds (aldehyde or ketone) to undergo Friedlaender condensation to give different 1,7-naphthyridines has been demonstrated. 2,4-Disubstituted 1,7-naphthyridine 8 was prepared from 3-amino-4-acetylpyridine (6) and ketone 4 (82%). The Friedlaender self-condensation of pyridyl substrate 6 is reported, as well. The dimer product, 2-(3-aminopyridin-4-yl)-4-methyl-1,7-naphthyridine (7), was obtained in 97% yield. 2-Aryl-and 2,3-diaryl-1,7-naphthyridines (16-18) were prepared from 3-aminoisonicotinaldehyde (13) and arylketones 4, 14, and 15 (28-71%). The key substrates 6 and 13 are readily available via the improved pyridine nitration method. Copyright

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.